Payment overview · 2025
General Payments
$876.60
53 reported records · 16 companies
Healthcare provider profile · identity verified
John Kelly, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BLOOMFIELD, NJ · NPI 1265540686
Verified facts
What the public records show
CMS Open Payments records show John Kelly, MD received $876.60 in general payments during 2025 across 53 reported records.
ABBVIE INC. accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Xifaxan by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $253.28 | 28.9% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.34 | 11.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.26 | 11.0% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $80.45 | 9.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.11 | 6.1% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $52.27 | 6.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $47.71 | 5.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.93 | 4.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.41 | 3.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.62 | 2.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.50 | 2.0% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $17.11 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.06 | 1.9% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.88 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.87 | 1.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $15.80 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $876.60 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $199.30 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $169.19 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $98.34 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $80.45 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $69.59 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.19 | 4 | 2025 |
Source payment records
|
|||||
| PANGEA Normalized: pangea |
Device | Stryker Corporation | $52.27 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $47.71 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.35 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.77 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.77 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $33.21 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.18 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $6.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 115 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 659 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 505 | 168 |
| Metformin Hcl | Metformin Hcl | 295 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 72 |
| Omeprazole | Omeprazole | 198 | 69 |
| Losartan Potassium | Losartan Potassium | 192 | 60 |
| Alprazolam | Alprazolam | 180 | 44 |
| Trazodone Hcl | Trazodone Hcl | 164 | 51 |
| Gabapentin | Gabapentin | 162 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 61 |
| Azithromycin | Azithromycin | 161 | 134 |
| Furosemide | Furosemide | 151 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 46 |
| Methylprednisolone | Methylprednisolone | 133 | 115 |
| Carvedilol | Carvedilol | 124 | 37 |
| Lisinopril | Lisinopril | 124 | 45 |
| Lorazepam | Lorazepam | 122 | 35 |
| Eliquis | Apixaban | 115 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 38 |
| Montelukast Sodium | Montelukast Sodium | 104 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 38 |
| Simvastatin | Simvastatin | 90 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 85 | 30 |
| Potassium Chloride | Potassium Chloride | 83 | 35 |
| Jardiance | Empagliflozin | 79 | 20 |
| Levofloxacin | Levofloxacin | 79 | 65 |
| Farxiga | Dapagliflozin Propanediol | 77 | 14 |
| Ozempic | Semaglutide | 76 | 14 |
| Enoxaparin Sodium | Enoxaparin Sodium | 75 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 19 |
| Meloxicam | Meloxicam | 64 | 20 |
| Donepezil Hcl | Donepezil Hcl | 62 | 19 |
| Famotidine | Famotidine | 62 | 19 |
| Allopurinol | Allopurinol | 60 | 27 |
| Mupirocin | Mupirocin | 60 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 53 |
| Cefuroxime | Cefuroxime Axetil | 58 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 41 |
| Mometasone Furoate | Mometasone Furoate | 53 | 43 |
| Glimepiride | Glimepiride | 52 | 15 |
| Ibuprofen | Ibuprofen | 49 | 31 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 16 |
| Meclizine Hcl | Meclizine Hcl | 46 | 26 |
| Sertraline Hcl | Sertraline Hcl | 46 | 15 |
| Prednisone | Prednisone | 45 | 37 |
| Celecoxib | Celecoxib | 44 | 18 |
| Dexamethasone | Dexamethasone | 44 | 39 |
| Linzess | Linaclotide | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 33 |
| Lactulose | Lactulose | 43 | 14 |
| Tramadol Hcl | Tramadol Hcl | 43 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 35 |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 39 | 36 |
| Metformin Hcl Er | Metformin Hcl | 39 | 12 |
| Olanzapine | Olanzapine | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | 13 |
| Fenofibrate | Fenofibrate | 37 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Xifaxan | Rifaximin | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Nystatin | Nystatin | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 19 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Naproxen | Naproxen | 27 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 23 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 22 |
| Nabumetone | Nabumetone | 23 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Austedo | Deutetrabenazine | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clarithromycin Er | Clarithromycin | 19 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 15 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 18 | 17 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Colchicine | Colchicine | 15 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Lidocaine | Lidocaine | 14 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Cefdinir | Cefdinir | 13 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Kristalose | Lactulose | 13 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | 12 |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Levocarnitine | Levocarnitine | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $876.60 · 53 records | ABBVIE INC. | AIRSUPRA, AUSTEDO XR, BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, INGREZZA, JARDIANCE, MOUNJARO, NEFFY, NURTEC ODT, Ozempic, PANGEA, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, WELLBUTRIN, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error